Integer Holdings Corp (ITGR) 2016 Q4 法說會逐字稿

Good afternoon. My name is Mike and I will be your conference operator today. At this time, I would like to welcome everyone to the Q4 2016 Integer Holdings Corporation earnings conference call.

(Operator Instructions)

I'll now turn the call over to Amy Wakeham, Vice President Investor Relations. You may begin your conference.

Thanks Mike. Good afternoon, everyone. Thanks for joining us and welcome to Integer's fourth quarter 2016 conference call.

This call is being webcast live, and together with our earnings release and conference call presentation are available on the Investor Relations section of our corporate website. The results and data we discuss today reflect the consolidated results of Integer for the periods indicated.

During our call, we will discuss certain non-GAAP measures. For a reconciliation to the most directly comparable GAAP measure, please see the appendix of today's presentation and the notes to the financial statements in today's earnings release.

As a reminder, statements about expected future events and financial results are forward-looking and subject to risks and uncertainties. Our actual results may differ. Please refer to the risk factors detailed in our SEC filings for further discussion.

For anyone listening to a taped or webcast replay or reviewing a written transcript of this conference call, please note that all information presented is current only as of today's date, February 27, 2017. The Company disclaims any duty or obligation to update any forward-looking information, whether as a result of new information, future events, or otherwise.

On the call today to discuss our quarterly results and to update you on our business outlook and strategic initiatives are Thomas J. Hook, President and Chief Executive Officer; Michael Dinkins, Executive Vice President and Chief Financial Officer. Tom Mazza, Corporate Controller, Treasurer and Interim Chief Financial Officer will join us for the Q&A portion of the call. Following our prepared remarks, the call operator will come back on the line for Q&A.

I would now like to turn the call over to Tom Hook.

Thank you, Amy. Welcome and thank you for joining us this afternoon. On today's call we will review our fourth-quarter results, provide our outlook for 2017, and give you an update on our business and product lines.

2016 has been a year full of significant change with good forward progress, despite several challenges. Just over a year ago, we completed the combination of Greatbatch and Lake Region Medical, and we have spent the past year successfully integrating the two legacy companies, positioning Integer as the global leader in medical device outsource manufacturing. Our broad suite of technologies from discrete products to complete implantable medical device systems, coupled with our expertise in comprehensive capabilities, is allowing us to deepen customer relationships and explore new ways to partner together both with existing and new customers.

Fourth-quarter results reflect continued stabilization and the return to a modest growth trajectory in our business. During the quarter, we announced the appointment of Jeremy Friedman as Chief Operating Officer with responsibility for our medical product lines. His leadership will allow us to strategically align and leverage our integrated capabilities more effectively to expand revenue opportunities with customers.

Operationally, we are making continued progress across the organization. Initiatives to reduce inventory levels across all product lines are delivering results. Inventory balances are down in excess of $25 million year over year, allowing us to accelerate pay down of debt obligations.

We have demonstrated continued fiscal discipline, and operating costs have decreased significantly during the second half of the year through a combination of Companywide cost reduction programs, realized integration synergies, and ongoing continuous improvement initiatives. Additionally, focused efforts to improve and enhance customer relationships are allowing us to better manage our business and product line forecasts.

From a financial perspective, revenue was essentially flat year over year and is slightly up on a sequential quarterly basis, this reflects continued good progress from the decline experienced during the first half of 2016. We made solid progress over the past year, particularly in integration, even as the business has been impacted by customer and industry headwinds. We also addressed internal challenges throughout the year, and believe we have a solid foundation to return to revenue growth as we head into 2017.

I would like to now turn the call over to Michael to discuss our fourth-quarter financial results in more detail and the outlook for the remainder of the year. I will be back later to discuss product line results and strategic growth initiatives. Michael?

Thanks, Tom, and good afternoon, everyone. Today, I will take you through our fourth-quarter financial results, our balance sheet metrics and introduce our 2017 full-year guidance.

Slide 7 highlights our key results for the quarter and total year. We had solid performance in the quarter, and we end the year on a positive trend as our revenue performance continues to improve although we acknowledge we still have a lot of work to do. Tom, when he covers the individual product categories, will give further insight on the progress we are making.

I want to highlight two things from this slide. First, our sales in the fourth quarter of 2016 were flat compared to the prior year at $360 million, and increased $13 million sequentially from the third quarter of 2016. Foreign currency exchange rates did not materially impact sales in comparison to the prior year. We ended 2016 with positive momentum, and we believe we are well positioned for incremental revenue growth as we look to 2017.

One of our top priorities is increasing our cash flow from operations so that we can reduce our debt as fast as possible. We made progress in 2016, with total cash flow from operations of $106 million which allowed us to reduce our debt by $46 million. We believe we have the processes and discipline to improve this performance in 2017 as you will see when we cover guidance in a few slides.

Let's review our revenue in a bit more detail. On a comparable organic constant currency basis, fourth-quarter 2016 revenues were flat compared with the fourth quarter of 2015. On a comparable organic constant currency basis, cardio and vascular revenue in the fourth quarter of 2016 increased by 7% over the comparable period of the prior year primarily driven by increased customer demand for electrophysiology and vascular access products.

On a comparable organic constant currency basis, cardiac and neuromodulation revenues decreased 5%. The year-over-year decrease is primarily driven by higher demand in the fourth quarter of 2015 as certain customers accelerated shipments prior to year end in order to meet contractual terms. Additionally, cardiac and neuromodulation sales were impacted by contractual price reductions given in exchange for longer-term volume commitments.

On a comparable organic constant currency basis, advanced surgical, orthopedics and clinical medical revenue decreased 3% year over year, primarily driven by a reduction in demand for certain products, as well as contractual price reductions given in exchange for longer-term volume commitments. Non-medical GAAP revenue for the fourth quarter of 2016 was $11.3 million, a 14% decrease from the fourth quarter of the prior year, primarily reflecting the slow down in the energy markets. Non-medical GAAP revenue increased 28% sequentially over the third quarter of 2016, reflecting the stabilization of our energy business.

Adjusted EBITDA for the fourth quarter of 2016 was $70.5 million on an as-reported and comparable basis, a 2% increase and an 11% decrease respectively compared with the fourth quarter of 2015. The decrease in comparable results reflected gross profit decline.

On a comparable basis, fourth-quarter 2016 gross profit increased 20% over the prior-year fourth quarter, primarily due to $23 million of inventory step up amortization recorded in 2015 in connection with the acquisition of Lake Region Medical. Excluding this amortization, gross profit declined $7.4 million on a comparable basis primarily due to contractual price reductions given in exchange for longer-term volume commitments, and the impact of higher warranty reserves and inventory obsolescence write-offs caused by various customer returns and field actions during the quarter.

One of our primary areas of focus is driving efficiencies to improve cash flow so we can accelerate debt repayment in order to reduce our leverage and increase shareholder value. Cash flow provided by operating activities for the fourth quarter of 2016 were approximately $34 million.

Capital expenditures were $11 million for the fourth quarter of 2016 and $59 million for the full year. We repaid $17 million of outstanding debt during the fourth quarter of 2016, bringing total debt repayment to $46 million for the year.

The initiative we implemented to improve cash flow are generating the desired results. Last quarter, we discussed reductions in our inventory levels, not only for the balance of 2016 but also for 2017, as a means to generate cash and continue to pay down debt. I am pleased to share that we exceeded our year-end target for inventory, and improved our inventory turn by one full notch.

And we see continued room for improvement, and expect to reduce overall inventory levels even further while not compromising our ability to meet the demands of our customers. The efforts of our supply chain team to rationalize the number of vendors we do business with, to realize synergies, and extend payment terms is driving desired results with reduced costs and improved cash flow management.

I would now like to discuss our outlook for 2017. We expect 2017 full-year revenue to be in the range of $1.39 billion to $1.43 billion, an increase of nearly 2% at the midpoint. We believe our revenue outlook, developed using a more mature integer forecasting process, appropriately balances product line growth opportunities with customer program risks.

We expect 2017 full-year adjusting earnings per diluted share to be in the range of $2.70 per share to $3.10 per share, an 8% increase at the midpoint of guidance. We closed out 2016 with positive momentum, and we have a solid foundation for growth in 2017.

As you can see from slide 12, we expect capital expenditures in the range of $50 million to $60 million for the year, and depreciation and amortization in the range of $95 million to $100 million for the year. Both of these numbers are consistent with our historical performance.

Our stock-based compensation is expected to be approximately $15 million for 2017. Most importantly, our working capital is expected to decline $10 million to $20 million for the year, primarily because of plans to reduce our inventory levels while maintaining our high customer service performance targets.

Our other operating expense is expected to be $18 million to $22 million for the year. A significant decrease from the $62 million incurred in 2016, reflecting lower integration and reduced spending. The combination of inventory reduction and lower integration spend will position us to pay down debt in 2017.

FY17 adjusted effective tax rate is expected to be approximately 25%. Cash taxes is expected to be approximately $10 million for the year.

I'll now turn the call back to Tom.

Thanks, Michael. I would now like to do a quick review of each of our product lines.

Turning to the advanced surgical and orthopedics product line which includes portable medical. Operationally, we closed out 2016 on a strong note. Customer relationships are advancing and we have made improvements in quality performance and inventory management practices, which have positively contributed to total Company cash flows.

Last quarter, we talked about the significant progress we have made advancing the wireless power initiative. During the fourth quarter, we shipped the first wireless prototype. Additionally, we are making good progress advancing a second customer relationship, while continuing conversations with a broad group of potential wireless customers.

The advanced surgical and orthopedics product line revenues remain a solid contributor to overall results. Product line revenues declined when compared to the fourth quarter of 2015, however in the prior year several customers increased demand at the end of the year in advance of product line transfers to our facility in Tijuana. As these product lines are fully qualified, we expect that revenue will return to normalized levels. Additionally, the advanced surgical and orthopedics product line is driven by customer product launches and in 2016 has been a slower launch year when compared to 2015.

Operational performance remained steady and we continued to see improving relationships at high levels of collaboration with our top customers. Multiple continuous improvement initiatives advancing across our operations are driving incremental cost savings. Additionally, operational and quality programs are in progress to standardize and harmonize our systems and processes across the product line.

In 2017, we expect incremental revenue growth opportunities driven by new product launches and acceleration in targeted areas. We believe there are multiple opportunities for Integer to successfully partner with customers to help them streamline and mitigate cost pressures by providing industry-leading solutions. I look forward to sharing more details on future calls.

Revenues in the cardio and vascular product line ended the year strong, increasing 7% year over year on a quarterly basis driven by strong demand for precious metal machining components and our OEM product lines. The outlook for 2017 is positive.

We continue to see strong demand for several key products, have successfully launched a significant co-development product, and had a number of new opportunities while positioned in the sales process. Customer relationships remain strong with greater penetration and increased opportunity with mid sized OEM customers. Accelerated interest and opportunity in co-development and OEM product offerings, and the near execution of several significant medium and long-term supply agreements will build momentum across the product line throughout 2017.

The cardiac rhythm management and neuromodulation product line delivered positive quarterly momentum, following the challenges experienced during the first half of 2016. Revenues improved, supported by deeper customer engagement and the completion of several new agreements during the quarter. By leveraging integrated product technology and manufacturing capabilities, customers are providing even more visibility into future opportunities, we expect these will translate into revenue growth in the future.

We believe that there are many growth opportunities within the neuromodulation market and also the CRM market, even though the overall market is flat to declining. OEM partners and customers are seeking more comprehensive, value-added solutions and supply chain efficiencies which integer is well-positioned to provide. We believe that the recent CMS approval for leadless pacing will accelerate adoption and further technological innovation in the CRM market.

Additionally, the neuromodulation market is rapidly growing. Our leading position to design and manufacture full, active implantable systems increases the total value we provide and ultimately capture as future revenue streams. We are focused on long-term business development to sustain and grow this product line into the future.

We also continued to accelerate short- and mid-term revenue opportunities. In addition to recently awarded new product development and manufacturing programs, we have a solid pipeline of future opportunities in various stages of development that provide us confidence as we head into 2017.

The recent FDA approval of an MRI safe pacemaker offered by a leading OEM provides incremental revenue growth opportunities. We are currently working closely with our customer partners to remain synchronized with their demand requirements and the longer-term opportunity for Integer. We look forward to sharing more information in future quarters as we progress in these areas.

Turning to non-medical sales. The Electrochem product line faced a challenging year throughout 2016, with the continued downturn in the oil and gas market. However during the fourth quarter, we saw the price of oil begin to stabilize, this has started to bring energy customer activity back online, particularly in North America, which has helped to improve Electrochem revenue a positive sign as we head into 2017.

As the energy market worked through these challenges, we remained focused on maintaining and growing our market share within this space. Additionally, we have worked hard to engage with customers across all the market segments we serve, and have made good progress on multiple new business opportunities with existing and new customers.

As we navigated the Electrochem product line through this challenging period, we took steps to protect our market share and parallel with adjusting our cost structure and reducing inventory levels to improve our return on invested capital. We expect to return to growth in 2017, based on the oil and gas industry market recovery and new business wins.

Last quarter, we shared Integer's high-level strategic objectives. First, we will invest to drive growth with customers across the full range of the products and services continuum. Second, we will deliver shareholder returns through growth and profitability and cash generation to drive accelerated repayment of debt obligations. And third, we will continue to cultivate an ethical value-driven culture that optimizes the commitment and contribution of our exceptional associate team.

We remain laser focused on achieving these objectives to realize our vision to enhance the lives of patients worldwide by being our customer's partner of choice for innovative medical technologies and services. Integration efforts remain on track, and we expect to be largely completed by the middle of 2017. We closed out 2016 exceeding our original synergies target of $25 million and at the top end of the range we provided last quarter, with cumulative synergies of $34 million.

Productivity initiatives to reduce direct and indirect spend, primarily through supplier negotiations and vendor consolidation, continue to advance and are generating the desired results. We expect to achieve $50 million of cumulative synergies by the end of 2017, and $60 million in 2018.

We recently completed several major integration milestones. First, the comprehensive integration of associate compensation and benefit plans. Second, the consolidation of finance and IT systems. And third, the process optimization within our sales and operating planning processes. Remaining activities are on schedule to further support our ability to successfully complete the formal integration of our Company in 2017.

We are advancing plans to leverage our manufacturing footprint, increased scale, (technical difficulties) and product capabilities to support the needs of our customers. These efforts include continuous improvement programs, productivity initiatives, direct material and indirect expense savings opportunities, and the establishment of global centers of excellence.

[Zoey] transfers and closures previously announced and in progress including the closure and transfer of our Clarence, New York facility, the completion of the Plymouth relocation, and full qualification our Tijuana facility are advancing towards completion. At this time, we do not have any additional plans to commence new projects to consolidate or close any manufacturing facilities. We are evaluating the plans and policies of the new US administration in parallel with assessing our operational infrastructure to meet customer needs and future growth.

Integer is well positioned within the medical technology and medical device outsource manufacturing markets. We believe there is a robust funnel of opportunities to pursue, it is contingent upon us to capitalize on these. We have expanded our medical device capabilities, and are excited about opportunities to partner with customers to drive innovation. We have the scale and global presence supported by world-class manufacturing and quality capabilities.

We are confident in our abilities as one of the largest medical device outsource manufacturers, with a long history of successfully integrating companies, driving down costs, and growing revenues over the long run. We continue to drive shareholder value by enhancing the lives of patients worldwide by being our customer's partner of choice for innovative medical technologies and services.

Before we open the call up for questions, let's discuss our Chief Financial Officer transition plan. Today, we announced the appointment of Gary Haire as the Executive Vice President and Chief Financial Officer. Gary has an extensive background in finance and operations, with significant experience in manufacturing and in distribution industries. We look forward to welcoming Gary aboard in early May.

As previously announced, our current Chief Financial Officer, Mike Dinkins, is retiring in early March. I'd like to thank Michael for his dedicated service to Integer over the past eight years, as a Board member and as a key member of the executive leadership team. Tom Mazza, Corporate Controller and Treasurer will serve as Interim Chief Financial Officer until Gary joins the Company.

Operator, we will now turn the question-and-answer portion of the call.

(Operator Instructions)

Matthew Mishan, KeyBanc.

Good afternoon, and thank you for taking the questions.

Hello, Matt.

Mike, Tom, could you go into a little bit more detail on the EBITDA miss versus your guidance? The sales were excellent right in the midpoint, but it looks like EBITDA came in about $10 million below at the midpoint.

The primary driver for the reduction in the EBITDA was both a mix of business that we have that drove the increase, it was a little bit lower margin business than some of the others. And the increase that we had in the fourth quarter were some warranty and inventory reserves that we set up reflecting some failed actions in terms of how our products had been performing in the marketplace. Those were the two drivers that were different than what we had provided in the guidance.

Could you quantify the higher warranty reserve and how much longer you expect to realize that?

The warranty reserves was approximately about half of the mix, roughly around $5 million. And the other was the mix of business in terms of lower margins. We believe that we have reflected on our balance sheet all the known items and do not expect that we will be materially dipping on reserves going forward.

Okay, great. That's very helpful. And how should we be thinking about pricing on an annual basis moving forward for you guys? You have been locking in a longer-term contracts with your customers.

Are you close to finishing doing that? Is that an ongoing process that's going to go on for you over time? How should we be thinking about that moving forward?

Matt, this is Tom Hook. It's a question that I believe that is inherent in medical device outsourcing on an annual basis. As we continue to engage customers, I believe that between 1% to 2% per year in price per activity in exchange for locking in development contracts and longer-term agreements is typically the expected norm.

And then we work with our customers to bring obviously new revenue streams online to compensate for those price productivities that we provide them. So that product pricing in the range of 1% to 2% is consistent over the future as it has been over the past.

Okay. And then we have a rising interest rate environment going into next year. How are you thinking about mitigating the interest rate volatility on the floating rate debt?

Roughly about 80% of our debt is fixed, up to a LIBOR of 1%. Because we have gone in and put in hedges in place for the term loan A, and the term loan B has a floor of 1%. We are monitoring interest rates at this point in time.

We have not put any hedge on the term loan B, but we'll continue to monitor it. The pricing right now on that was something we did not feel was a good course of action that we should take. But until LIBOR goes above 1%, we're about almost 80% fixed.

All right, perfect. And last question, can you talk about how you are improving customer satisfaction? Maybe some of the metrics that you are using and how they have trended over the last several years?

Yes. We have a series of measures that would be from a service perspective that would be based on on-time delivery and quality performance, and we track those by product line, actually by SKU and roll them up into each location, each product line, and each customer. And we report on those actively in operating review meetings, both internally and directly with customers, we share the data openly with them.

Beyond that, we also work on partnerships and co-developments. As you know, we're active innovators and we want to take those innovations and deploy them with customers into active product development programs that they are running. So we're opening up our portfolio of capabilities to them to be able to partner with.

So we have measures from a technology standpoint that are internal of how we are partnering with customers to be able to, whether on a component or a subassembly or a full system, be able to ingrain that co-development together to be able to have a true partnership between the customer and Integer. And we openly track and report that with customers.

And then ultimately as you know, Matt, that all precipitates out into revenues as the customer launched that product and demand that we provide to them. So our ability to deliver that with flawless levels of quality is critical for us to get the revenues and profitability that we deserve, and of course we track that at the end of the project and on an ongoing basis.

Thank you very much.

Jim Sidoti, Sidoti and Company.

Good afternoon. Can you hear me?

Yes, Jim.

I am sorry if you've covered this already, I joined a little late. But if you look at the two businesses that were down the most in 2016, the neuromodulation and the Electrochem businesses, do you think you've bottomed out at this point? And do you expect -- I know you said Electrochem should be growing next year, do you expect neuro must will be growing next year as well or this year 2017 as well?

Jim, thanks for the question. Yes, clearly Electrochem because of the oil and gas industry bottomed out in 2016, and is beginning a modest recovery. We expect that customers will start drawing more demand from us and have in the fourth quarter, both to respond to their own market demands in the industry as well as replenishing their inventory, both of which are positive to us.

As a correction, we report cardiac rhythm management and neuromodulation together as a product line. Our cardiac rhythm management products have seen most of the pressure in 2016, neuromodulation has been a positive influence and growing for us. So we expect that as we continue through into 2017, neuromodulation will continue to grow because of the market size and high growth rate.

And we intend to capitalize on that because of the customer base we have and the success we have been enjoying. We expect obviously cardio rhythm management while a mature market, we still feel that it's opportunity rich with our current customers. It just won't be anywhere near the high growth rate as neuromodulation.

All right. And have you seen any major changes or material changes from your largest customer, St. Jude, as a result of the acquisition from by Abbott?

We have not seen any material changes, other than the obvious publicly disclosed ones around the management of how they are going to run their combined company. There's obviously some news with some recent product approvals that they have had. Beyond that as it applies to Integer, both Abbott and St. Jude are very strong customers for us.

We have deep relationships with both. And as they are making transition plans of how they are managing the business, we are working in concert with them. And just to remind you, Jim, the legacy companies with Integer have long-term agreements and arrangements with St. Jude and Abbott that allow for a large amount of predictability to the business going forward.

And because of our tight partnerships, we have a very active funnels and development and co-development projects with both Abbott and St. Jude that are feeding the funnel for future revenue opportunities. So we are bullish for the prospects going forward of the combination of the two companies as one of our largest customers.

All right. Thank you.

Charles Haff, Craig-Hallum.

Hey, guys, thanks for taking my questions. I wanted to step back for a minute and think about your business from a long-term, normalized basis on revenue growth. Med device volume growth I guess I think about as a 3% business for OEMs in the aggregate, but realize that you guys have individual business lines and segments that you are in. But I am curious to hear your thoughts on where you think volume growth should be for your business.

And then if I layer in the 1% to 2% price decline per year in exchange for the long-term agreements, is it correct to think about this as a 2% normalized revenue growth business? Or are there volume growth differences or mix benefits that you get from moving higher up the value chain? I am just trying to understand the long-term revenue growth picture.

Charles, I think you described two of those variables correctly. I think there is two other variables that have to be included in the longer-term growth prospects.

The first one I will say is what we will call the product continuum. Today, Integer sells everything from discrete products and components all the way to complete systems. So even if the market is at the -- our end customer is growing low single digit, if we can capture a higher percent of content of the devices and sell more sub assemblies and complete medical devices to a customer, even in a low-growth market, we can continue to grow at a higher rate than the end markets that they are selling in.

Additionally, the fourth variable is technologic breakthroughs. We actively spend tens of millions of dollars a year in research and development in fundamental technologies that are not represented in the end markets today. Where we can co-develop those products with customers and have new product offerings that transcend what is available today, many time opening up new market opportunities and new technologies that actually create new markets or create new opportunities in existing markets.

Each of the four pieces that are highlighted here, unit growth obviously, price exposure, technological improvements, as well as selling a richer mix in the product continuum, all four of those pieces will result in the longer-term growth trajectory. We don't provide obviously long-term guidance, but we've felt historically the mid- to single-digit revenue growth range is a good target for us over the longer run and that is what it has been historically. 2017 is a recovery year for us given the challenges of 2016, but our plans are obviously to over the longer run is to get back to that trajectory and be able to leverage that stronger to the bottom line in the way we partner with our customers.

Okay. And then a follow up to that. So for the long-term volume commitments that you have been getting recently in exchange for price then, is that targeted towards getting this higher share of wallet? Are these new programs that you have seen yourself then starting with the OEMs, or is this just keeping what you have, if you will?

This is our way -- I think if you step back to the bigger picture question, Charles, is customers obviously want to launch new products. And they also want to have some level of productivity in their current products because they are facing price pressure in the clinical medical device market.

In forming a long-term agreement, we work together with the customer to work on cost reduction opportunities where we are both saving money. So while we are passing price to the customer from Integer, we are also cutting our own costs that we pass on to the customers.

To the importance of a long-term agreement, is it gives us a longer period of time to make those investments and returns and it allows us to have certainty that those investments will pay off when we perform. So the best way to look at that long-term agreements is we are doing them in partnerships with customers, we are not bartering back and forth between us.

The long-term agreements cover many times the existing book of business, but it also cover the next generation sets of product lines that would be added over the term of the agreement, which are sometimes 5, 8, sometimes as long as 10 years in place. That way a customer knows that we are incentivized to not only just drive new technologies, but as those technologies are introduced into the market, by driving business and volume, we can also do active cost-reduction projects, give price productivity to them, and drive efficiencies for them downstream. And that is all comprehended in those long-term agreements.

So we view and our customers view it's good business. It is a close partnership. We have been highly successful with this in both legacy companies, and we intend to continue to use the practice and as we win them we will continue to report them out to investors.

Okay, great. Then two more quick ones, and I'll jump back in the queue. For gross margin guidance for 2017, what do you anticipate a range of gross margins could be?

The guidance that we provide at the level of detail is what we like to stay at, Charles. We don't really go down into guidance on a gross margin basis.

Okay. And then lastly on Mexico. You've obviously been increasing your production in Tijuana for the last few years. And there has been in a lot of rhetoric coming out in terms of equalization, taxes, and so forth.

I am wondering if you could just help me understand what types of tactical changes that you are contemplating? And if you know your product mix of products that come out of Mexico, that would be helpful as well. Thank you.

Certainly. Charles, this is Tom, and I'll let Mike chime in here. We are very committed to our teams, both in Juarez and both facilities we have in Tijuana and the Integer team, and we work very closely with customer operations all over the world. We are from those operations importing into the US, but also exporting to other countries a substantial portion of that production.

Both of our operations there function as [Mikeel] at [Orez], we are very closely tracking the new US administration's policies on how that would work. It is a bit premature to comment on what we plan to do until we understand what those policies will be. But they potentially could have an effect on us, but we feel confident we can still leverage the capabilities we have there very effectively in the future.

I will co-sign what Tom is saying that a good portion of what we produce at the facilities are being shipped other than to the US, and a significant portion of what is being produced at those facilities is actually for a Swiss entity that would not necessarily be covered with the things that are proposed at this particular point in time.

But we're going to continue to monitor it, but we don't see any major issues at this particular point in time. And most importantly, as Tom emphasized, our facilities in Mexico are really doing a fantastic job for us and great quality for our customers.

And the last piece of your question, Charles, was with regard to a breakout. We don't provide a breakout, but we know qualitatively you understand what products we've moved down to our facilities over time over the past decade. But we don't provide any breakdown of what we do down in our Mexico facilities from a revenue basis.

Okay. Thanks for taking my questions.

Thanks, Charles.

(Operator Instructions)

Matt Mishan, KeyBanc.

Great, thanks for taking the follow up. Could you guys talk about the cadence of revenue growth in 2017?

I think the last couple years or at least all around the initial revenue growth guidance, it was more back-half weighted. How should we think about it this year, especially with potentially a major product launch for you guys in the first quarter from a major OEM customer and CRM?

Matt, you have a lot you are asking underneath that question. We're going to not provide quarterly revenue guidance this year, but yes, it is true there is a periodicity to quarterly revenues with customers. They order on different cycles because of year ends are not always annual year ends.

If you look to our historical periods of time, you can get a flavor of what some of those cadences are, Q1, Q2, Q3, Q4. And we feel that 2017 will be a net 2% growth rate, but there will be variation between the quarters.

And traditionally, we have slight variations. We have European businesses that tend to add in the third quarter. We tend to have in the first quarter is not necessarily our strongest, we have stronger second and fourth quarters. The same periodicity historically will tend apply going forward that we don't feel that that's going to be much different.

Okay, that is fair. And then what was the strategic rationale to focus on adjusted EBIT -- EPS for guidance versus adjusted EBITDA like you have in the past?

We felt that that adjusted EBITDA was a transition year reporting mechanism during a period of time where we were quickly and aggressively integrating the companies, and had a lot of information to convey. We feel now that typical to most other public companies, the reporting revenues and adjusted EPS is the proper way forward now that we are an integrated entity under one brand, one operating team. So we feel that is the better way to give information from a performance standpoint to investors prospectively.

Okay. And then lastly, what is the free cash flow expectation for 2017?

We believe that the details that we gave in the guidance will allow you to get some indication of that, but it will be somewhere right around $150 million.

Did you say $115 million or $150 million?

I just realized you said free cash flow. So then subtract from that as we indicated about $50 million to $60 million for our CapEx.

Mike, did you say $115 million or $150 million for operating cash flow?

Closer to $150 million.

Perfect. Thank you very much.

That is all the time we have for questions today. Thank you for participating in today's conference. That does conclude today's program, and you may all disconnect. Everyone have a great day.